%20Ver-2.png)
Many hematologic malignancies persist within the bone marrow and circulation, where malignant cells evade conventional therapies and can return even after treatment.
Liberate’s oncology programs focus on enabling genetic medicines to reach all of the relevant places in the body. We can re-program cells to target the cancer cells both in the blood and in the bone marrow.
Multiple Myeloma
Our initial oncology treatment centers on multiple myeloma, using monocytes and macrophages genetically programmed to target cancer cells that express a protein called BCMA. By targeting cells expression BCMA, the monocytes and macrophages are able to selectively kill the malignant and cancerous plasma cells.
This strategy is designed to:
• Target cancerous cells within the bone marrow itself
• Find and destroy malignant cells in the blood
• Train the immune system all over the body to continue to target and destroy the cancerous cells.
The program aims to establish a new approach to treating hematologic cancers aligned with disease biology.
